
Please try another search
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.
Name | Age | Since | Title |
---|---|---|---|
David Gardner | - | - | Member of Scientific Committee |
Juliet Thompson | 59 | 2017 | Independent Non-Executive Director |
Geneviève Bourg-Heckly | - | - | Member of Scientific Committee |
Lyn Dafydd Rees | 52 | 2023 | CEO & Executive Director |
Marco Zonta | - | - | Member of Scientific Committee |
Jean-Pierre Crinelli | - | - | Independent Non-Executive Director |
Isabelle Cartier | - | - | Member of Scientific Committee |
John Robert Brown | 70 | 2023 | Non-Executive Chairman |
Ian David Gilham | 65 | 2024 | Independent Non-Executive Director |
Steve Gibson | - | 2017 | CFO, Company Secretary & Director |
Joanne Mason | 50 | 2024 | Chief Scientific Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review